← Human Trials & Peer-Reviewed Studies

Determination of nicotine absorption from multiple tobacco products and nicotine gum.

Plain-language guide to PMID 22585541 (2013): open-label randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID
22585541
Journal
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
Year
2013
Study type
Randomized Controlled Trial
Authors
Digard H et al. (5 authors)
DOI
10.1093/ntr/nts123

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

The objective of this study was to determine nicotine absorption for current pouched and loose snus products in comparison with a cigarette and an over-the-counter nicotine gum.

Why It Was Studied

Snus is a smokeless tobacco product traditionally used in Scandinavia and available in pouched or loose forms.

Who Took Part

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

The researchers conducted an open-label, randomized, 6-way, crossover study involving 20 healthy snus and cigarette users.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Everyone knew when Therapeutic nicotine (patch, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

One of 6 products (2 pouched snus, 2 weights of loose snus, a cigarette, and a nicotine gum) was administered at each of 6 visits.

Blood samples were taken at intervals over 120 min and sensory perception assessed by questionnaire.

What Was Measured

PubMed files the paper under topics including Area Under Curve, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 CYP2A6, Heterozygote, Lip, Nicotine and Salivation.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.